Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
| ▸ | TEC | P42680 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.61 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.61 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423119 | 0.94 | EGFR (0.88) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3393640 | 0.90 | EGFR (0.81) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3425469 | 0.88 | EGFR (0.87) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3391775 | 0.88 | EGFR (0.79) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL9883243 | 0.88 | EGFR (0.79) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3420763 | 0.88 | EGFR (0.86) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3434405 | 0.87 | EGFR (0.77) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL13259707 | 0.87 | EGFR (0.77) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3700589 | 0.87 | EGFR (1.00) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3390572 | 0.85 | EGFR (1.00) | EGFRERBB2RIPK2RETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167492-B1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI SCIENCE CO LTD (KR) | 2015-10-14 | — | — | EP | claimed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | claimed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | claimed |
| EP-2167492-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | Hanmi Pharm. Co., Ltd. (KR) | 2010-03-31 | — | — | EP | claimed |
| WO-2008150118-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | claimed |
| EP-2167492-B1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI SCIENCE CO LTD (KR) | 2015-10-14 | — | — | EP | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2167492-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | Hanmi Pharm. Co., Ltd. (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008150118-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885RIPK2 841/4885 |
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | ARCN1, APP, ADAM17 | EGFR 3325/4885ERBB2 4671/4885RIPK2 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.